Allogene Therapeutics, Inc. (ALLO) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-18

Key Insights

The reporting person, David D. Chang, who is the President and CEO of Allogene Therapeutics, Inc. (ALLO), sold 47,763 shares of common stock on March 16, 2026, likely to cover tax withholding obligations related to the vesting of restricted stock units.
Chang also holds a significant indirect beneficial ownership of Allogene's common stock, with 856,044 shares held in the RTC 2019 Trust and another 856,044 shares held in the JEC 2019 Trust, as well as an additional 1,201,108 shares held in the Chang 2006 Family Trust.
The sale of shares to cover tax obligations is a routine practice, but the continued significant indirect ownership by the CEO suggests a positive long-term outlook for the company.

Want the newest filings?

This analysis covers the filing from 2026-03-18. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-18

The reporting person, Benjamin Machinas Beneski, who is the SVP and Chief Technical Officer of Allogene Therapeutics, Inc. (ALLO), sold 4,835 shares of the company's common stock to cover tax withholding obligations related to the vesting of restricted stock units.
The shares were sold at a weighted average price of $2.47, which is within the range of $2.46 to $2.47 per share.
The reported transaction is a mandatory 'sell to cover' transaction to satisfy tax withholding obligations and does not represent a discretionary trade by the reporting person.

Filed: 2026-02-04

Insider Arie Belldegrun has acquired a significant number of Allogene Therapeutics shares, indicating potential confidence in the company's future prospects.
Belldegrun owns shares directly as well as indirectly through various trusts and investment vehicles, suggesting a diversified ownership structure.
The granting of stock options and restricted stock units to Belldegrun further aligns his interests with those of Allogene Therapeutics shareholders.

Filed: 2026-02-04

The reporting person, Zachary Roberts (EVP of R&D), sold 35,700 shares of Allogene Therapeutics, Inc. (ALLO) common stock at a weighted average price of $1.77 per share to cover tax withholding obligations related to the vesting of restricted stock units.
Roberts also received a new stock option grant for 718,763 shares with a strike price of $1.87, vesting over 4 years, and 203,307 restricted stock units that will vest over 4 years.
The insider selling, while mandatory to cover taxes, may indicate a cautious sentiment about the company's near-term prospects, though the new equity grants suggest a longer-term commitment to Allogene.

Filed: 2026-02-04

The reporting person, Annie Yoshiyama, sold 4,167 shares of Allogene Therapeutics common stock at a weighted average price of $1.72 to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was mandated by the company's equity incentive plan and does not represent a discretionary trade.
The reporting person was granted 179,691 stock options with an exercise price of $1.87, which will vest over a 4-year period starting February 2, 2027. This indicates the company is providing long-term incentives to retain key talent.
The reporting person was also granted 50,827 restricted stock units, which will vest in 4 equal annual installments starting February 2, 2026. This further aligns the interests of the reporting person with those of shareholders.

Filed: 2026-02-04

Douglas Earl Martin, SVP and General Counsel of Allogene Therapeutics, sold 22,900 shares of common stock on February 2, 2026, at an average price of $1.76 per share, potentially to cover tax withholding obligations related to the vesting of restricted stock units.
Martin also received a grant of 539,072 stock options and 152,480 restricted stock units on February 2, 2026, vesting over a four-year period, indicating the company's continued commitment to incentivize and retain its executive team.
The reported transaction appears to be a routine, non-discretionary sale to cover tax obligations, rather than a voluntary sale of shares, which may suggest the executive's continued confidence in the company's long-term prospects.

Filed: 2026-02-04

The reporting person, Geoffrey M. Parker, who is the Chief Financial Officer of Allogene Therapeutics, Inc., sold 24,001 shares of the company's common stock to cover tax withholding obligations related to the vesting of restricted stock units.
The reporting person was granted 539,072 stock options and 152,480 restricted stock units, which will vest over time, indicating an alignment of the CFO's interests with those of the company and its shareholders.
The volume and timing of the stock sales suggest the reporting person's transactions were routine in nature and not indicative of any significant concerns about the company's prospects.

Filed: 2026-02-04

The reporting person, David D. Chang, who is the President and CEO of Allogene Therapeutics, Inc. (ALLO), sold 95,269 shares of the company's common stock to cover tax withholding obligations in connection with the vesting of restricted stock units.
Chang also holds a significant number of shares in the company, both directly and indirectly through various trusts, indicating his alignment with the company's long-term success.
The company granted Chang additional stock options and restricted stock units, which vested over a multi-year period, further aligning his interests with those of shareholders.

Filed: 2026-02-04

The reporting person, Benjamin Machinas Beneski, sold 7,549 shares of Allogene Therapeutics, Inc. (ALLO) common stock at an average price of $1.73 to cover tax withholding obligations related to the vesting of restricted stock units.
Beneski was granted 373,757 stock options and 105,720 restricted stock units, with the stock options vesting over a 4-year period and the RSUs vesting in 4 annual installments.
The insider selling was mandatory to cover tax obligations and not a discretionary trade, indicating no immediate concern about the company's outlook.

Filed: 2026-01-23

The reporting person, Zachary Roberts, who is the EVP of R&D at Allogene Therapeutics, Inc. (ALLO), sold 26,269 shares of the company's common stock to cover tax withholding obligations related to the vesting of restricted stock units.
The sale was not a discretionary trade but rather a mandatory 'sell to cover' transaction as per the company's equity incentive plan, indicating the reporting person did not choose to sell the shares.
The reporting person still owns a significant 616,866 shares of the company's common stock following the reported transaction, suggesting continued confidence and investment in the company.

Other reports for Allogene Therapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.